ClinicalTrials.gg
CompletedNCT01734928OPTIMISMMUpdated Jun 6, 2023Results posted

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of Pomalidomide and Bortezomib in Multiple Myeloma, sponsored by Celgene. Completed at 321 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
559
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
7th of 102
559 · median 50
Started
2013
with 3 others
Phase 3
17 of 102
3 open now
Registered
19th of 102
by date
Lead sponsor
10 of 102
Celgene

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 7th largest by enrollment, is one of 4 that started in 2013, is one of 17 in phase 3, and was the 19th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Pomalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥ 18 years at the time of signing .
  • Must have documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis.
  • Must have had at least 1 but no greater than 3 prior anti-myeloma regimens.
  • Must have documented disease progression during or after their last anti-myeloma therapy.
  • All subjects must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles.

Exclusion criteria

Exclusion Criteria:

  • Documented progressive disease during therapy or within 60 days of the last dose of a bortezomib-containing therapy under the 1.3 mg/m\^2 dose twice weekly dosing schedule.
  • Peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization.
  • Non-secretory multiple myeloma.
  • Subjects with severe renal impairment requiring dialysis.
  • Previous therapy with pomalidomide.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
559 participants (actual)

Study arms

  • Experimental
    Pomalidomide, Bortezomib and Low Dose Dexamethasone

    4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.

    Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone

  • Active comparator
    Bortezomib and Low Dose Dexamethasone

    1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day \[≤ 75 years old\]or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.

    Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.

    Also known as: Oral Pomalidomide, CC-4047

  • Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.

    Also known as: Velcade

  • Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival by Independent Response Adjudication Committee (IRAC)

    Progression free survival (PFS) will be calculated as the time between the randomization and progressive disease (PD) or death. Progressive Disease is defined as an Increase of ≥ 25% from nadir in: * Serum M-component and/or (the absolute increase must be ≥ 0.5 g/dL)g * Urine M-component and/or (the absolute increase must be ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels, the absolute increase must be \> 100 mg/dL. * Bone marrow plasma cell percentage, the absolute % must be ≥ 10%h * Definite development of new bone lesions or soft tissue plasmacytomas increase in the size of existing bone lesions or soft tissue plasmacytomas. -Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.

    Time frame: From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) is calculated as the time from randomization to death from any cause.

    Time frame: From randomization to date of death, up to approximately 65 months

  2. Overall Response Rate by Independent Response Adjudication Committee (IRAC)

    The ORR together with the relative proportions in each response category (ie, stringent CR \[sCR\], CR, very good PR \[VGPR\], PR, SD, and PD) by treatment using the IMWG criteria will be examined. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease

    Time frame: From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months

  3. Duration of Response by Independent Response Adjudication Committee (IRAC)

    Duration of myeloma response is defined as the duration from the time when the IMWG response criteria are first met for sCR or CR or VGPR or PR until the first date the response criteria are met for PD or until the subject died from any cause, whichever occurs first. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease

    Time frame: From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months

  4. Number of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE)

    Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.

    Time frame: From first dose to 28 days after the last dose (up to approximately 44 months

  5. Number of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE)

    Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.

    Time frame: From first dose to 28 days after the last dose (up to approximately 44 months

07

Results

Posted Jun 6, 2023

Participant flow

Randomization
Participant flow — Randomization
MilestoneTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Started281278
Completed278270
Not completed38
Withdrew: Physician decision01
Withdrew: Clinical progression01
Withdrew: Progressive disease02
Withdrew: Withdrew informed consent04
Withdrew: Death10
Withdrew: Randomization error10
Withdrew: Lost to follow-up10
Treatment Period
Participant flow — Treatment Period
MilestoneTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Started278270
Completed00
Not completed278270
Withdrew: Lost to follow-up02
Withdrew: Progressive disease167165
Withdrew: Adverse event3952
Withdrew: Withdrawal of consent2522
Withdrew: Death209
Withdrew: Other reasons2719
Withdrew: Pregnancy01

Outcome measures

PrimaryProgression Free Survival by Independent Response Adjudication Committee (IRAC)

Progression free survival (PFS) will be calculated as the time between the randomization and progressive disease (PD) or death. Progressive Disease is defined as an Increase of ≥ 25% from nadir in: * Serum M-component and/or (the absolute increase must be ≥ 0.5 g/dL)g * Urine M-component and/or (the absolute increase must be ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels, the absolute increase must be \> 100 mg/dL. * Bone marrow plasma cell percentage, the absolute % must be ≥ 10%h * Definite development of new bone lesions or soft tissue plasmacytomas increase in the size of existing bone lesions or soft tissue plasmacytomas. -Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.

Time frame:
From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months
Reported as:
Median · Months
Progression Free Survival by Independent Response Adjudication Committee (IRAC)
MonthsTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Progression Free Survival by Independent Response Adjudication Committee (IRAC)11.20 (9.66 to 13.73)7.10 (5.88 to 8.48)
Statistical analysis
  • Treatment 1: POM+BTZ+LD-DEX vs Treatment 2: BTZ+LD-DEX · Based on Cox proportional hazards model · p = 0.001 · Hazard ratio (hr): 0.61 · 95% CI 0.49 to 0.77
SecondaryOverall Survival (OS)

Overall survival (OS) is calculated as the time from randomization to death from any cause.

Time frame:
From randomization to date of death, up to approximately 65 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Overall Survival (OS)35.58 (28.55 to 41.20)31.61 (26.05 to 37.16)
Statistical analysis
  • Treatment 1: POM+BTZ+LD-DEX vs Treatment 2: BTZ+LD-DEX · Log Rank · p = 0.571 · Hazard ratio (hr): 0.94 · 95% CI 0.77 to 1.15Based on Cox proportional hazards model, comparing the hazard functions associated with treatment groups, stratified by age, prior number of anti-myeloma regimens, and beta-2 macroglobulin at Screening.
SecondaryOverall Response Rate by Independent Response Adjudication Committee (IRAC)

The ORR together with the relative proportions in each response category (ie, stringent CR \[sCR\], CR, very good PR \[VGPR\], PR, SD, and PD) by treatment using the IMWG criteria will be examined. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease

Time frame:
From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months
Reported as:
Count of participants · Participants
Overall Response Rate by Independent Response Adjudication Committee (IRAC)
ParticipantsTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Stringent complete response92
Complete Reponse359
Very Good Partial Response10440
Partial Response8388
Stable Disease32106
Progressive Disease1116
Not Evaluable717
SecondaryDuration of Response by Independent Response Adjudication Committee (IRAC)

Duration of myeloma response is defined as the duration from the time when the IMWG response criteria are first met for sCR or CR or VGPR or PR until the first date the response criteria are met for PD or until the subject died from any cause, whichever occurs first. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease

Time frame:
From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months
Reported as:
Median · Months
Duration of Response by Independent Response Adjudication Committee (IRAC)
MonthsTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Duration of Response by Independent Response Adjudication Committee (IRAC)13.70 (10.94 to 18.10)10.94 (8.11 to 14.78)
Statistical analysis
  • Treatment 1: POM+BTZ+LD-DEX vs Treatment 2: BTZ+LD-DEX · Unstratified log-rank test · p = 0.064 · Hazard ratio (hr): 0.76 · 95% CI 0.56 to 1.02Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups
SecondaryNumber of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE)

Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.

Time frame:
From first dose to 28 days after the last dose (up to approximately 44 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE)
ParticipantsTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Number of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE)259194
SecondaryNumber of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE)

Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.

Time frame:
From first dose to 28 days after the last dose (up to approximately 44 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE)
ParticipantsTreatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEX
Number of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE)2912

Adverse events

Collected over AEs and SAEs: From first treatment to 28 days after last dose, up to approximately 44 months on average of 10 months. All-Cause mortality: from randomization to end of the study, approximately 65 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment 1: POM + BTZ + LD-DEX197/281 (70.1%)177/278 (63.7%)276/278 (99.3%)
Treatment 2: BTZ + LD-DEX193/278 (69.4%)119/270 (44.1%)260/270 (96.3%)
Most frequent serious events
Showing 10 of 277
Most frequent serious events
EventTreatment 1: POM + BTZ + LD-DEXTreatment 2: BTZ + LD-DEX
PneumoniaInfections and infestations34/27817/270
PyrexiaGeneral disorders12/2785/270
InfluenzaInfections and infestations10/2784/270
Lower respiratory tract infectionInfections and infestations10/2785/270
General physical health deteriorationGeneral disorders5/2789/270
Atrial fibrillationCardiac disorders9/2782/270
Pulmonary embolismRespiratory, thoracic and mediastinal disorders9/2781/270
Acute kidney injuryRenal and urinary disorders8/2786/270
DiarrhoeaGastrointestinal disorders5/2786/270
Septic shockInfections and infestations6/2780/270
Most frequent other events
Showing 10 of 70
Most frequent other events
EventTreatment 1: POM + BTZ + LD-DEXTreatment 2: BTZ + LD-DEX
NeutropeniaBlood and lymphatic system disorders150/27829/270
Peripheral sensory neuropathyNervous system disorders134/278103/270
ThrombocytopeniaBlood and lymphatic system disorders110/278105/270
FatigueGeneral disorders107/27872/270
ConstipationGastrointestinal disorders106/27865/270
DiarrhoeaGastrointestinal disorders102/27882/270
Oedema peripheralGeneral disorders101/27854/270
AnaemiaBlood and lymphatic system disorders87/27872/270
PyrexiaGeneral disorders72/27833/270
Upper respiratory tract infectionInfections and infestations71/27851/270

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEXTotal
Mean65.9 ± 10.1366.1 ± 10.1666.0 ± 10.14
Sex: Female, Male
Sex: Female, Male(Participants)Treatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEXTotal
Female126131257
Male155147302
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEXTotal
Hispanic or Latino171431
Not Hispanic or Latino244241485
Unknown or Not Reported202343
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment 1: POM+BTZ+LD-DEXTreatment 2: BTZ+LD-DEXTotal
American Indian or Alaska Native000
Asian14822
Native Hawaiian or Other Pacific Islander000
Black or African American81321
White237234471
More than one race000
Unknown or Not Reported222345
08

Study locations

321 sites
  • Southern Cancer Center
    Mobile, Alabama 36608, United States
  • Arizona Oncology
    Tucson, Arizona 85710, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • University of California San Francisco Fresno Campus
    Fresno, California 93701, United States
  • Marin Oncology Associates
    Greenbrae, California 94904-2007, United States
  • Moore UCSD Cancer Center
    La Jolla, California 92083, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Sutter Pacific Medical Foundation
    Santa Rosa, California 95403, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06489, United States
  • Local Institution - 153
    Southington, Connecticut 06489, United States
  • George Washington Medical Center
    Washington, District of Columbia 20037, United States
  • Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • University Cancer Institute
    Boynton Beach, Florida 33426, United States
  • Broward Oncology Associates PA
    Fort Lauderdale, Florida 33308, United States
  • Broward Oncology Assoc.
    Fort Lauderdale, Florida 33316, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Alves Domenech Oncology and Hematology Clinic
    Hollywood, Florida 33021, United States
  • Palm Beach Cancer Institute, LLC
    West Palm Beach, Florida 33401, United States
  • Local Institution - 135
    Marietta, Georgia 30060, United States
  • Northwest Georgia Oncology Centers, PCWilliam S. Gibbons Center Research Institute
    Marietta, Georgia 30060, United States
  • University of Chicago
    Chicago, Illinois 60637-1470, United States
  • Investigative Clinical Research of Indiana, LLC
    Indianapolis, Indiana 46254, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Western Kentucky Hematology and Oncology Group, PSC
    Paducah, Kentucky 42003, United States
  • Tulane University Medical Center
    New Orleans, Louisiana 70112, United States
  • Cancer Care of Maine
    Bangor, Maine 04401, United States
  • Local Institution - 132
    Bangor, Maine 04401, United States
  • St. Agnes - Medical Center
    Baltimore, Maryland 21229-5299, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Local Institution - 125
    Bethesda, Maryland 20817, United States
  • Medstar Health Research Institute
    Hyattsville, Maryland 20782, United States
  • Local Institution - 299
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Local Institution - 100
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Local Institution - 298
    Boston, Massachusetts 02215, United States
  • Henry Ford Medical Center - New Center One
    Detroit, Michigan 48202-268, United States
  • Local Institution - 178
    Detroit, Michigan 48202-268, United States
  • Cancer and Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49546, United States
  • Detroit Clinical Research Center
    Lansing, Michigan 48912, United States
  • Beaumont Cancer Center
    Royal Oak, Michigan 48073, United States
  • Essentia Health Duluth CCOP
    Duluth, Minnesota 55805, United States
  • Metro MN CCOP
    Saint Louis Park, Minnesota 55416, United States
  • Columbia Comprehensive
    Jefferson City, Missouri 65203, United States
  • Kansas City VA Medical Center University of Kansas Medical Center
    Kansas City, Missouri 64128, United States
  • St John's Mercy Medical Center
    Saint Louis, Missouri 63141, United States
  • St. John's Clinic Cancerand Hematology - Springfield
    Springfield, Missouri 65804, United States
  • Billings Clinic
    Billings, Montana 59102, United States
  • Southeast Nebraska Cancer Center
    Lincoln, Nebraska 68510, United States
  • CarePoint Health Research Institute
    Jersey City, New Jersey 07306, United States
  • Hematology-Oncology Associates of NNJ, P
    Morristown, New Jersey 07960, United States
  • Somerset Hematology-Oncology Associates
    Somerville, New Jersey 08876, United States
  • Local Institution - 186
    Bronx, New York 10467, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Stony Brook University
    Stony Brook, New York 11794-7300, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Eastern Institute of Medical Sciences
    Greenville, North Carolina 27834, United States
  • Boice-Willis Clinic P.A.
    Rocky Mount, North Carolina 27804, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Local Institution - 111
    Canton, Ohio 44718, United States
  • MetroHealth Medical Systems
    Cleveland, Ohio 44109, United States
  • Mid Ohio Oncology Hematology Inc
    Columbus, Ohio 43219, United States
  • University of Toledo Medical Center
    Toledo, Ohio 43614, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Med Univ of South Carolina
    Charleston, South Carolina 29425, United States
  • Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute
    Spartanburg, South Carolina 29303, United States
  • Avera Research Institute
    Sioux Falls, South Dakota 57105, United States
  • Local Institution - 167
    Watertown, South Dakota 57201, United States
  • Prairie Lakes Health Care System
    Watertown, South Dakota 57201, United States
  • University of Tennessee Medical Center - Cancer Institute
    Knoxville, Tennessee 37885, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-5505, United States
  • Local Institution - 114
    Dallas, Texas 75390, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Brooke Army Medical Center Francis Street Medical Center
    Fort Sam Houston, Texas 78235-8200, United States
  • Local Institution - 103
    Fort Sam Houston, Texas 78235-8200, United States
  • Local Institution - 130
    Houston, Texas 77090, United States
  • Northwest Cancer Center
    Houston, Texas 77090, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Utah Cancer Specialist
    Salt Lake City, Utah 84106, United States
  • Huntsman Cancer Institute at the University of Utah
    Salt Lake City, Utah 84112, United States
  • Swedish Cancer Inst
    Seattle, Washington 98104, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • Wenatchee Valley Hospital and Clinics
    Wenatchee, Washington 98801, United States
  • Local Institution - 139
    Morgantown, West Virginia 25606, United States
  • West Virginia University CTRU
    Morgantown, West Virginia 25606, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Local Institution - 136
    Milwaukee, Wisconsin 53226, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Hospital St. Polten
    St. Pölten, 3100, Austria
  • Local Institution - 523
    St. Pölten, 3100, Austria
  • Local Institution - 480
    Vienna, 1090, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Local Institution - 481
    Vienna, 1160, Austria
  • Wilhelminenspital-Center for Hematology and Oncology
    Vienna, 1160, Austria
  • Local Institution - 308
    Oshawa, Ontario L1G 2B9, Canada
  • RSM Durham Regional Cancer Center - Lakeridge Health Oshawa
    Oshawa, Ontario L1G 2B9, Canada

Showing the first 100 of 321 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. PubMed 31097405 ↗
  • Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2. Erratum In: Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5. PubMed 28642620 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in May 2022, 112 months.

Results were first posted in Jun 2023, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 112 months is above that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2012
First posted
Nov 28, 2012
StartActual
Jan 7, 2013
Primary completionActual
May 9, 2022
CompletionActual
May 13, 2022
Results first posted
Jun 6, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01734928
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 28, 2012
Start date
Jan 7, 2013
Primary completion
May 9, 2022
Completion
May 13, 2022
Results posted
Jun 6, 2023
Last update
Jun 6, 2023

Study contacts

Bristol Myers-Squibb
study director · Bristol-Myers Squibb
Amine Bensmaine, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion